BGNE Well Stocked, APVO On A Roll, GMED Hits ALL-time High

The following are some of the biotech stocks that made their way onto the Day’s Gainers list of December 4, 2017.

GAINERS

1. BeiGene Ltd. (BGNE)

Gained 16.67% to close Monday’s (Dec.4) trading at $94.50.

News: No news

Pipeline:

The Company’s pipeline includes BGB-3111, BGB-A317 and BGB-290.

Clinical trials:

A pivotal phase II trial in China of BGB-3111 in relapsed/refractory mantle cell lymphoma; a global phase III trial of BGB-3111 compared to bendamustine and rituximab in treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma patients; a global pivotal phase II trial of BGB-3111 in combination with GAZYVA in relapsed or refractory follicular lymphoma patients; and a pivotal phase II trial in China of BGB-3111 in Waldenström’s macroglobulinemia; a global phase III trial of BGB-3111 compared to bendamustine and rituximab (BR) in treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) patients and a global pivotal phase II trial of BGB-3111 in combination with GAZYVA in relapsed or refractory follicular lymphoma (FL) patients are underway.

BGB-A317 is under a phase II trial in China in relapsed/refractory classical Hodgkin’s lymphoma; a global phase 1a/1b trial in advanced tumors; phase III trial in China as a second- or third-line treatment for patients with advanced lung cancer; pivotal phase II trial in China in previously treated, PD-L1-positive, locally advanced or metastatic urothelial cancer; phase II trial in China in combination with chemotherapy as a first-line treatment for patients with advanced lung cancer; and a phase II trial in China in combination with chemotherapy as a first-line treatment for patients with locally advanced or metastatic esophageal, gastric, or gastroesophageal junction carcinoma.

BGB-290 is under a global phase I trial in combination with temozolomide in locally advanced or metastatic solid tumors, and under a global Phase 1b/2 trial in combination with radiation therapy and/or temozolomide in glioblastoma.

Near-term catalysts:

— Present additional phase I data for BGB-3111 in non-Hodgkin’s lymphoma, updated Phase 1 data for the combination of BGB-3111 and Gazyva, and initial phase I data for the combination of BGB-3111 and BGB-A317 at the ASH Meeting that is to be held December 9-12, 2017 in Atlanta, GA.
— Initiate phase III trials of BGB-A317 in China in the fourth quarter of 2017 or the first quarter of 2018.
— Initiate a pivotal trial of BGB-290 in China in the fourth…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *